Why the study?
Does the metabolically healthy obesity (MHO) subphenotype predict future metabolic abnormalities and clinical disease?
Does the metabolically healthy obesity (MHO) subphenotype predict future metabolic abnormalities and clinical disease?
Metabolically healthy obesity is not a benign long-term condition, as most individuals eventually develop metabolic abnormalities and clinical disease.
Over time, most MHO participants developed metabolic abnormalities and clinical disease. The MHO subphenotype is a harbinger of future risk.
No takes yet. Share an insight, caveat, or question.
Echouffo‐Tcheugui et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: